Stock INVA INNOVIVA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Innoviva, Inc.

Equities

INVA

US45781M1018

Market Closed - Nasdaq
Other stock markets
 01:30:00 22/06/2024 am IST 		5-day change 1st Jan Change
15.9 USD -1.06% Intraday chart for Innoviva, Inc. -0.06% -0.87%
18/06 Cantor Fitzgerald Initiates Innoviva at Overweight Rating MT
10/06 Transcript : Innoviva, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 01:20 PM

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
BU
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
AQ
Innoviva : Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam Durlobactam or SUL DUR) for Hospital Acquired and Ventilator Associated Pneumonia Caused by Acinetobacter Baumannii Calcoaceticus Complex in China
PU
Innoviva: Q1 Earnings Snapshot
AQ
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
BU
Innoviva to Participate in the BofA Securities Health Care Conference
BU
Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
AQ
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
BU
Innoviva: Q4 Earnings Snapshot
AQ
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
BU
Innoviva Specialty Therapeutics Appoints David Altarac, MD, as Chief Medical Officer
AQ
Innoviva Specialty Therapeutics - Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
AQ
Innoviva: Q3 Earnings Snapshot
AQ
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
BU
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
BU
Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week 2023
AQ
Innoviva to Participate in the Cantor Global Healthcare Conference
BU
Innoviva - XACDURO, the First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia in Adults
AQ
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults
BU
Innoviva Appoints Stephen Basso as Chief Financial Officer
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INVA Stock
  4. News Innoviva, Inc.
  5. Press Releases